Table 4.
Simulated typical darunavir pharmacokinetic parameters and probability of therapeutic exposure for standard and doubled ritonavir boosting
| AUCta (mg·h/L) | AUCua (mg·h/L) | C trough, t (mg/L) | C trough, u (mg/L) | Probability of TAt (%) | Probability of TAu (%) | |
|---|---|---|---|---|---|---|
| Pregnant (GA = 38 weeks) | ||||||
| 800/100 mg q24h | 58 | 7.6 | 1.1 | 0.12 | 78 | 94 |
| 600/100 mg q12h | 82 | 11 | 2.1 | 0.25 | 96 | 99 |
| 800/200 mg q24hb | 59 | 7.7 | 1.1 | 0.12 | 80 | 94 |
| 600/200 mg q12hb | 83 | 11 | 2.1 | 0.28 | 96 | 100 |
| 1200/100 mg q24hb | 78 | 11 | 1.4 | 0.16 | 87 | 97 |
| 800/100 mg q12hb | 102 | 15 | 2.6 | 0.31 | 99 | 100 |
| Non-pregnant | ||||||
| 800/100 mg q24h | 76 | 8.0 | 1.6 | 0.14 | 92 | 97 |
| 600/100 mg q12h | 107 | 12 | 2.9 | 0.28 | 99 | 100 |
| 800/200 mg q24hb | 77 | 8.1 | 1.6 | 0.14 | 93 | 97 |
| 600/200 mg q12hb | 107 | 12 | 2.9 | 0.28 | 99 | 100 |
| 1200/100 mg q24hb | 102 | 12 | 2.1 | 0.19 | 96 | 98 |
| 800/100 mg q12hb | 132 | 16 | 3.5 | 0.35 | 100 | 100 |
GA, gestational age; Ctrough, concentrations at the end of the dosing interval; TA, therapeutic exposure; t, total; u, unbound.
a
Values refer to the daily exposure (0–24 h for both q24h and q12h dosing).
b
Explored darunavir/ritonavir dosing regimens.